Three patients have been treated with the OncoSil™ device in the Netherlands at the PANCOSIL Investigator-Initiated Clinical Trial. The trials are being conducted at the AMC Medical Centre in Amsterdam in collaboration with OncoSil Medical. 

This Trial tests the safety and feasibility of percutaneous radionuclide therapy (RNT), a form of treatment that can be performed with the OncoSil™ device in patients with advanced pancreatic cancer.  Over 20 patients are expected to be treated in this controlled trial, using the OncoSil™ device by percutaneous application throughout the PANCOSIL Trial. 

Who is Pancosil 

PANCOSIL is a Netherlands-based investigator-initiated clinical Trial set up in collaboration with OncoSil Medical. It is looking at the safety and feasibility of the percutaneous radionuclide therapy (RNT) with the OncoSil™ device. The aim is to ensure that interventional radiology and oncology can use the OncoSil™ device to treat patients. 

What is Percutaneous radionuclide therapy (RNT)

During the RNT procedure, a radioactive agent is delivered through internal radiation directly to the tumor using the Oncosil device. Internal radiation is better because it makes it possible to deliver “higher radiation doses” without sparring surrounding tissues. 

Is there any progress with Oncosil’s medical trials? 

• Control trials lend legitimacy to Oncosil, which could accelerate approval by regulators. 
• Faster approvals will increase the adoption of OncoSil across cancer treatment classes across the world. 
• Faster commercialisation will increase net revenues - as it has in the past - allowing the company to break even sooner. 
• Return on investment (ROI) to rise and the share price could recover in a sustained manner. 

Three patients have been treated with the OncoSil™ device in the Netherlands in a process known as the Percutaneous Radionuclide Therapy (RNT) that targets radioactive agents to the cell internally without impacting surrounding tissue. This is good news for OncoSil devices and the results of the control trials will improve OncoSil’s marketability and competitiveness.